Characteristics and prospects for hepatitis C therapy of an HIV-HCV coinfected population followed at a reference HIV Center

HIV Clinical Trials

Volumn 6, Issue 6, 2005, Pages 329-336

  Maida, Ivana ^a,b   Soriano, Vincent ^a   Ramos, Belén ^a   Ríos, Pilar ^a   González Lahoz, Juan ^a   Núñez, Marina ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

HIV; HVC; Interferon a; Liver; Ribavirin

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EXPOSURE; DRUG INDICATION; FEASIBILITY STUDY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPAIN; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS CARRIER; VIRUS REPLICATION;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL;

EID: 33644774913     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/25KL-0VTL-JWXP-FE6Y     Document Type: Article

References (41)

1. Di Martino V, Rufat P, Boyer N, et al. The influence of HIV coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology. 2001;34:1193-1199.
2. Mohsen A, Easterbrook P, Taylor C, et al. Impact of HIV infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut. 2003;52:1035-1040.
3. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis. 2001;32:492-497.
4. Martín-Carbonero L, Soriano V, Valencia E, García-Samaniego J, López M, González-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses. 2001; 17:1467-1472.
5. Rosenthal E, Poiree M, Pradier C, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS. 2003;17:1803-1809.
6. Pérez-Olmeda M, Núñez M, García-Samaniego J, Romero M, Martín-Carbonero L, Soriano V. Pegylated interferon alpha 2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS. 2003;17:1023-1028.
7. Chung R, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin vs interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459.
8. Torriani F, Rodríguez-Torres M, Rockstroh J, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.
9. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. JAMA. 2004;292:2839-2848.
10. Laguno M, Murillas J, Blanco J, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004;18:F27-F36.
11. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. AIDS. 2004;18:1-12.
12. Pérez-Olmeda M, Ríos P, Núñez M, García-Samaniego J, Romero M, Soriano V. Virological characteristics of hepatitis C virus infection in HIV-infected individuals with chronic hepatitis C: implications for treatment. AIDS. 2002;16:493-495.
13. García-Benayas T, Blanco F, Soriano V. Weight loss in HIV-infected patients. N Engl J Med. 2002;347:1287-1288.
14. National Institutes of Health. Consensus Development Conference: management of hepatitis C. Final statement. Gastroenterology. 2002;123:2082-2099.
15. Stark K, Schreier E, Muller R, Wirth D, Driesel G, Bienzle U. Prevalence and determinants of anti-HCV seropositivity and of HCV genotype among intravenous drug users in Berlin. Scand J Infect Dis. 1995;27:331-337.
16. Vitale F, Villafrate M, Viviano E, et al. Distribution of hepatitis C virus genotypes among intravenous drug users. A ten-year study in Palermo, Sicily. New Microbiol. 1998;21:335-342.
17. Bonacini M, Govindarajan S, Black L, Schmid P, Conrad A, Lindsay K. Patients co-infected with HIV and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat. 1999;6:203-208.
18. Franchini M, Rossetti G, Tagliaferri A, et al. The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders. Blood. 2001;98:1836-1841.
19. Rai R, Wilson L, Astemborski J, et al. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology. 2002;35:1247-1255.
20. Sherman K, Rouster S, Chung R, Rajicic N. Hepatitis C virus prevalence among patients infected with HIV: a cross-sectional analysis of the US ACTG. Clin Infect Dis. 2002;34:831-837.
21. Fleming C, Craven D, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and HIV coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis. 2003;36:97-100.
22. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341(8):556-562.
23. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med. 1999;340:1228-1233.
24. Piasecki B, Lewis J, Reddy K, et al. Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology. 2004;40:892-899.
25. Spada E, Mele A, Berton A, et al. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut. 2004;53:1673-1681.
26. Buffet-Janvresse C, Peigue-Lafeuille H, Benichou J, et al. HIV and HCV co-infection: situation at six French university hospitals in the year 2000. J Med Virol. 2003;69:7-17.
27. Fultz S, Justice A, Butt A, et al. Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with HIV infection. Clin Infect Dis. 2003;36:1039-1046.
28. Rauch A, Egger M, Reichen J, Furrer H, and the Swiss HIV Cohort Study. Chronic hepatitis C in HIV-infected patients: low elegibility and applicability of therapy with pegylated interferon-α plus ribavirin. J Acquir Immune Defic Syndr. 2005; 38:238-240.
29. Restrepo A, Johnson T, Widjaja D, et al. The rate of treatment of chronic hepatitis C in patients coinfected with HIV in an urban medical centre. J Viral Hepatitis. 2005;12:86-90.
30. Butt A, Wagener M, Shakil A, Ahmad J. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepatitis. 2005;12:81-85.
31. Mayers R, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. AIDS. 2004;18:75-79.
32. Thomas D, Shih J, Alter H, et al. Effect of HIV on hepatitis C virus infection among injecting drug users. J Infect Dis. 1996;174:690-695.
33. Hayashi K, Fukuda Y, Nakano I, et al. Poor response to interferon treatment for chronic hepatitis C in HIV-infected haemophiliacs. Haemophilia. 2000;677-681.
34. Kuehne F, Bethe U, Freedberg K, Goldie S. Treatment for hepatitis C virus in HIV-infected patients: clinical benefits and cost-effectiveness. Arch Intern Med. 2002;162:2545-2556.
35. Uberti-Foppa C, De Bona A, Morsica G, et al. Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;33:146-152.
36. Puoti M, Torti C Ripamonti D, et al. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr. 2003;32:259-267.
37. Vento S, Di Perri G, Cruciani M, Garofano T, Concia E, Bassetti D. Rapid decline of CD4+ cells after IFN-alfa treatment in HIV-1 infection. Lancet. 1993;341:958-959.
38. Pesce A, Taillan B, Rosenthal E, et al. Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1-infected patients. Lancet 1993;341:1597.
39. Soriano V, García-Samaniego J, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with HIV. Hepatitis-HIV Spanish Study Group. Clin Infect Dis. 1996;23:585-591.
40. Mauss S, Klinker H, Ulmer A, et al. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count. Infection. 1998;26:16-19.
41. Fried M. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36(suppl):237-244.